VMD

Viemed Healthcare, Inc. (VMD) SWOT Analysis Analysis (2026)

Invetso Score: 6/10 — Balanced · Last Updated: 2026-08-01

Strengths

Healthy profitability with gross margin at 57.2% and net margin at 4.8%.

Solid cash generation with free cash flow yield of 8.6% and FCF conversion near 48.1% of operating cash flow.

Low leverage and strong coverage metrics, including debt-to-equity of 0.08 and interest coverage of 17.2x.

Weaknesses

Operating margin remains modest at 8.1%, limiting earnings power despite strong gross margins.

Liquidity is only adequate, with a current ratio of 1.13 and cash ratio of 0.22.

SG&A remains heavy at 47.3% of revenue, which constrains operating leverage.

Opportunities

Valuation is reasonable at 1.13x sales and 11.6x free cash flow, leaving room for multiple expansion if execution stays steady.

Return on invested capital of 11.0% suggests the business can still compound capital efficiently.

Low debt burden gives the company flexibility to invest or return capital without stressing the balance sheet.

Threats

Thin net margin of 4.8% leaves earnings vulnerable to cost inflation or reimbursement pressure.

Working capital efficiency is good, but the business still depends on maintaining disciplined collections and inventory management.

No dividend support means equity returns rely entirely on operating performance and valuation.

Overall Score

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Viemed Healthcare, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →